Search the Newsreel

Intuitive Expands Manufacturing Footprint in Asia Pacific with New Facility in Penang, Malaysia

New 316,000-square-foot facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032 PENANG, Malaysia, Aug. 17, 2026 /PRNewswire/ -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), announced …

Why STAAR Surgical (STAA) Is Up 8.1% After Returning To Profit Under New CEO Warren Foust – And What's Next

Why STAAR Surgical (STAA) Is Up 8.1% After Q2 Profit Rebound And New CEO Appointment

Oppenheimer Just Upgraded Intuitive Surgical Stock. Here's Why.

Intuitive Surgical Inc location sign-by Sundry Photography via iStock Analysts at Oppenheimer recently upgraded the medtech company Intuitive Surgical (ISRG) from "Perform" to "Outperform" and set a $500 price target, implying a 24.6% upside from current levels. Expecting the company to benefit from the …

STAAR Surgical (STAA) Gives Warren Foust The CEO Role After Its Profit Reset

STAAR Surgical has appointed Warren Foust as its permanent President and CEO, following a period of operational reset and a return to profitable growth under his interim leadership. Foust's promotion from COO and interim co-CEO signifies a defined leadership direction for the ophthalmic device …

STAAR Surgical (STAA) Stock May Be 13% Below Fair Value Following Q2 Earnings Preview

S&CO Inc. Acquires New Holdings in Intuitive Surgical, Inc. $ISRG

S&CO Inc. has acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by purchasing 5,121 shares valued at approximately $2.04 million in the second quarter. This move comes as Intuitive Surgical reported strong quarterly results, exceeding analyst estimates with earnings of $2.80 per share …

Quantinno Capital Management LP Takes $1.11 Million Position in STAAR Surgical Company $STAA

Quantinno Capital Management LP has acquired a new position in STAAR Surgical Company, purchasing 59,302 shares valued at approximately $1.11 million. This makes Quantinno Capital Management LP a 0.12% stakeholder in the company, which has seen its revenue increase by 111.1% year-over-year in the …

Intuitive Surgical (ISRG): 3 Reasons We Love This Stock

Intuitive Surgical (ISRG): 3 Reasons We Love This Stock Over the last six months, Intuitive Surgical's shares have sunk to $400.75, producing a disappointing 17.5% loss - a stark contrast to the S&P 500's 13% gain. This might have investors contemplating their next move. …

Wall Street Zen Downgrades Intuitive Surgical (NASDAQ:ISRG) to Hold

Wall Street Zen downgraded Intuitive Surgical (NASDAQ:ISRG) from "Buy" to "Hold," despite a broader "Moderate Buy" consensus among analysts with an average price target of $508.68. Intuitive Surgical recently surpassed quarterly estimates with $2.80 EPS and $2.89 billion in revenue, representing an 18.4% year-over-year …

Staar Surgical Co (STAA) Shares Surge 3.4% -- What GF Score of 80 Tells Investors

Staar Surgical Co (STAA) shares surged 3.4% to $26.19, with a GF Score of 80/100, indicating strong overall performance. The stock is considered "Modestly Undervalued" by GuruFocus, with a potential upside of 21.8% from its current price, although its high P/E ratio and lack …

Intuitive Surgical (ISRG) Is Facing Fresh Competition In U.S. Surgical Robotics

Intuitive Surgical (ISRG) is facing new competition in the U.S. surgical robotics market as Johnson & Johnson's Ottava system received FDA authorization. Ottava's space-saving design and integration with J&J's existing surgical tools pose a direct challenge to Intuitive Surgical's da Vinci systems, potentially impacting …

Intuitive Surgical Inc. stock underperforms Friday when compared to competitors

Intuitive Surgical Inc. (ISRG) shares fell 1.68% to $394.51 on Friday, underperforming the broader market as the S&P 500 and Dow Jones also experienced slight declines. The company's stock closed 34.67% below its 52-week high, which was set on January 7th. This report highlights …

Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build

King Street Capital discloses 4.6% Surgery Partners (SGRY) holding in Schedule 13G

King Street Capital Management, L.P., along with King Street Capital Management GP, L.L.C., and Brian J. Higgins, have reported a joint beneficial ownership of 6,058,141 shares of Surgery Partners, Inc. (SGRY) common stock. This holding represents 4.6% of the company's outstanding shares, based on …

SurgePays (SURG.US)$ i sold i wasnt patient 🤣🤣🤣 but my 1 left over share. couple members from my DC traderslink hit though. students becoming the teacher🤣

A Moomoo community member, Smokey The Bear, shared that they sold their shares of SurgePays (SURG.US) due to lack of patience, keeping only one share. They noted that some members from their "DC traderslink" successfully profited, likening it to students teaching the teacher. The …

SurgePays Reports Q2 2026 Revenue Growth of 40.7% Year-Over-Year to $16.2 Million, Reports Positive Net Income of $1.29 Million

SurgePays, Inc. (NASDAQ: SURG) announced strong financial results for Q2 2026, with revenue increasing by 40.7% year-over-year to $16.2 million and achieving a positive net income of $1.29 million. The company's first-half revenue grew by 45.7% to $32.19 million, marking its sixth consecutive quarter …

SurgePays Edges up on Releasing Q2 Figures

SurgePays, Inc. announced strong financial results for the second quarter ended June 30, 2026, marking a return to GAAP profitability with net income of $1.29 million. The company reported significant revenue growth, reaching $16.20 million in Q2 and $32.19 million for the first half …

STAAR Surgical (STAA) reports 8.4% stake held by Madison Avenue group

A group of investment entities associated with Eli Samaha, collectively known as the Madison Avenue group, has reported a beneficial ownership of 8.4% in STAAR Surgical Company (STAA) as of June 30, 2026. This stake represents 4,175,748 shares of Common Stock out of 49,788,495 …

SurgePays Stock Skyrockets Following Return to Q2 Profitability and Strong Revenue Growth

SurgePays Inc. (NASDAQ: SURG) saw its stock price sharply increase after reporting strong Q2 2026 financial results, including a return to GAAP profitability and significant revenue growth. The company's revenue rose 40.7% year-over-year to $16.20 million, beating consensus estimates, and it posted a net …

SurgePays, Inc. (SURG) Q2 Earnings and Revenues Surpass Estimates

SurgePays, Inc. (SURG) reported Q2 earnings of $0.05 per share, significantly surpassing the Zacks Consensus Estimate of a loss of $0.11 per share. The company also exceeded revenue expectations, posting $16.21 million against an estimate of $13.80 million. Despite these strong quarterly results, SurgePays …

SURG Looks 82.3% Undervalued on GF Value™

SurgePays Inc (SURG) is highlighted as potentially 82.3% undervalued based on its GF Value™ despite significant operational challenges and an extremely low GF Score of 31/100. The company reported a 23% increase in smartphone rent-to-own sales in July, but faces persistent losses and negative …

SurgePays turns profitable amid continuing growth | 2026-08-14 | Investing News

SurgePays Q2 EPS $0.05 beats estimate; revenue up 41% to $16.2m

SurgePays returns to profit in Q2 FY26; revenue rises 40.7% to $16.2 million year over year

SurgePays reported a return to profit in Q2 FY26, with net income reaching $1.29 million, or $0.05 EPS, and operating income swinging to a profit of $3.5 million. The company's revenue increased by 40.7% year-over-year to $16.2 million, and first-half revenue grew 45.7% to …

$SurgePays (SURG.US)$ full exit 0.4. But sill LFG. 🍀🤞🏻🥳 thanks bro @Smokey The Bear 🍻

A moomoo user, skies686, announced a full exit from SurgePays (SURG.US) at 0.4, expressing gratitude to another user, @Smokey The Bear. Despite the exit, the user remains optimistic and uses the phrase "LFG" (Let's F***ing Go), indicating continued enthusiasm. The post is a brief …

SurgePays Reports Q2 and First-Half 2026 Results, Returns to GAAP Profitability and Delivers Strong Revenue Growth

SurgePays, Inc. announced its Q2 and first-half 2026 financial results, reporting a return to GAAP profitability with a net income of $1.29 million in Q2 and strong revenue growth. First-half revenue increased by 45.7% year-over-year to $32.19 million, driven by diversified revenue streams and …

Surgery Partners (SGRY) Reaffirmed Guidance On Revenue Growth, Is It Still A Bargain?

Surgery Partners (SGRY) has garnered attention after reaffirming its full-year guidance and emphasizing a focus on higher acuity procedures, despite continued net losses. The company's stock is considered 15.4% undervalued, with a fair value estimated at $17.95, driven by the migration of high-acuity surgical …

UBS Adjusts Price Target on STAAR Surgical to $19 From $20, Keeps Sell Rating

UBS has adjusted its price target for STAAR Surgical Company (STAA) to $19, down from $20, while maintaining a Sell rating on the stock. This update reflects the analyst's current outlook on the medical equipment company. The article also notes recent company activities including …

Intuitive Surgical, Inc.: Konsensus der Analysten und Kursziel | 888024 | US46120E6023

STAAR Surgical (STAA) Stock Price Shrugs Off Profit Rebound As China Dominates

STAAR Surgical reported a strong Q2 2026, returning to profit with $8.1 million in net income and $93.5 million in sales, largely driven by significant growth in China. Despite these positive results, the stock price barely moved, reflecting investor concerns about the company's heavy …

Jefferies cuts STAAR Surgical stock price target on estimate update

Jefferies has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $28 from $29, while maintaining a Hold rating, following the company's second-quarter 2026 results. STAAR Surgical reported Q2 revenue of $93.5 million, beating consensus estimates, with strong China sales, but missed earnings per …

STAAR Surgical Company Q2 2026 Earnings Call Summary

STAAR Surgical reported record first-half revenue, driven by the successful launch of EVO Plus in China, which helped gain market share despite a challenging refractive market. The company is strategically shifting to a platform approach, with plans for new product development and a transition …